Equities Analysts Offer Predictions for TSBX Q1 Earnings

Turnstone Biologics Corp. (NASDAQ:TSBX) – Analysts at Leerink Partnrs issued their Q1 2026 EPS estimates for shares of Turnstone Biologics in a research report issued on Tuesday, April 1st. Leerink Partnrs analyst D. Graybosch forecasts that the company will post earnings per share of ($0.13) for the quarter. The consensus estimate for Turnstone Biologics’ current full-year earnings is ($3.32) per share. Leerink Partnrs also issued estimates for Turnstone Biologics’ Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.13) EPS and Q4 2026 earnings at ($0.13) EPS.

Turnstone Biologics (NASDAQ:TSBX) last issued its earnings results on Friday, March 28th. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.13.

Separately, Piper Sandler cut Turnstone Biologics from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $3.75 to $0.40 in a report on Wednesday, February 5th.

Turnstone Biologics Stock Down 8.3 %

Shares of NASDAQ:TSBX opened at $0.38 on Wednesday. The business’s 50 day moving average is $0.41 and its 200 day moving average is $0.47. The stock has a market cap of $8.70 million, a P/E ratio of -0.12 and a beta of 2.04. Turnstone Biologics has a 52-week low of $0.34 and a 52-week high of $3.88.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Turnstone Biologics stock. Takeda Pharmaceutical Co. Ltd. acquired a new stake in shares of Turnstone Biologics Corp. (NASDAQ:TSBX) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 895,824 shares of the company’s stock, valued at approximately $448,000. Turnstone Biologics makes up about 1.7% of Takeda Pharmaceutical Co. Ltd.’s investment portfolio, making the stock its 8th largest position. Takeda Pharmaceutical Co. Ltd. owned 3.87% of Turnstone Biologics as of its most recent SEC filing. 52.51% of the stock is owned by hedge funds and other institutional investors.

Turnstone Biologics Company Profile

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas.